Cytokinetics (CYTK) Announces Proposed $150M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Cytokinetics (CYTK) Prices 7.29M Share Common Offering at $24/Sh
July 17, 2020 5:56 AM EDTCytokinetics, Incorporated (NASDAQ: CYTK) today announced the pricing of an underwritten public offering of 7,291,667 shares of its common stock at a price to the public of $24.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting... More
Cytokinetics (CYTK) PT Raised to $29 at JMP Securities
July 15, 2020 4:17 AM EDTJMP Securities raised its price target on Cytokinetics (NASDAQ: CYTK) to $29.00 (from $23.00) while maintaining a Market Outperform rating.... More
Cytokinetics (CYTK) PT Raised to $38 at H.C. Wainwright, After Licensing Collaboration Announced
July 14, 2020 12:12 PM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Cytokinetics (NASDAQ: CYTK) to $38.00 (from $35.00) while maintaining a Buy rating.
... MoreCytokinetics (CYTK) PT Raised to $33 at Piper Sandler, After Licensing Collaboration Announced
July 14, 2020 11:11 AM EDTPiper Sandler analyst Edward A. Tenthoff raised the price target on Cytokinetics (NASDAQ: CYTK) to $33.00 (from $28.00) while maintaining a Overweight rating.
... MoreCytokinetics (CYTK) Reports Licensing Collaboration & Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor
July 14, 2020 7:32 AM EDTCytokinetics, Incorporated (NASDAQ: CYTK) today announced that it has agreed to a series of transactions with certain companies wholly owned by investment funds managed by RTW Investments, LP, and Ji Xing Pharmaceuticals Limited (Ji Xing), related to CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor that Cytokinetics is developing for the potential treatment of hypertrophic cardiomyopathies (HCMs) and other clinical indications that may be associated with excessive cardiac muscle contractility. Pursuant to these transactions, Cytokinetics will receive a combination of committed capital, funding and sale proceeds of up to $250 million from RTW and is eligible to... More
